A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2016
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2014 Results published in the Drugs and Aging.
- 10 May 2010 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History